MARLBOROUGH, Mass., May 10, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including four late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific Program, in Paris, on May 16-19. The late-breaking clinical trials include the following:
SCHEDULE OF PRESENTATIONS OF INTEREST (listed chronologically)
Tuesday, May 16
The company will also host an investor event and webcast on Tuesday, May 16, from 16:00 to 17:00 (CEST)/ 10:00 to 11:00 AM (EDT) to discuss its interventional cardiology and structural heart portfolios. The live webcast and replay will be accessible at www.bostonscientific.com/investors with the latter becoming available approximately one hour following the completion of the event.
*The LOTUS™ valve system is currently not available for use or sale.**In the U.S., the Agent™ Paclitaxel-Coated balloon catheter is investigational and not available for sale.
About Boston ScientificBoston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
CONTACTS:
U.S. Media: Trish Backes(612) [email protected]
European Media: Chiara Ennas+44 (0) 7766 [email protected]
Investor Relations: Susie Lisa, CFA(508) 683-5565 (office)[email protected]
Advertisement
- Evaluation of 30-day safety and one-year efficacy outcomes from the REPRISE III trial, a prospective, randomised investigation of the LOTUS™ Valve System*, a transcatheter aortic valve implantation (TAVI) device against the CoreValve® TAVI System (Medtronic).
- The LOTUS Valve RESPOND study providing one-year, 'real-world' clinical and device performance outcomes data.
- Three-year outcomes of the EVOLVE II trial assessing the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System in patients with diabetes.
- Data from the EWOLUTION registry, a prospective multicenter study of 'real-world' outcomes with the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device.
Advertisement
SCHEDULE OF PRESENTATIONS OF INTEREST (listed chronologically)
Tuesday, May 16
- The LOTUS Valve System: A prospective, randomised investigation of a novel TAVI system: the REPRISE III trial: Ted E. Feldman, M.D., will present at 12:30 in the Main Arena.
- The LOTUS Valve System: The RESPOND study at one-year: primary endpoint outcomes with a repositionable and fully retrievable aortic valve in routine clinical practice: Nicolas Van Mieghem, M.D., Ph.D., will present at 16:03 in the Maillot room.
- SYNERGY Stent: Outcomes after PCI with a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: three-year results from the EVOLVE II diabetes substudy: Martine Gilard, M.D., will present at 11:35 in the Maillot room.
- The LOTUS Valve System: Thirty-day outcomes in patients treated with a repositionable and fully retrievable aortic valve designed to reduce the incidence of conduction disturbances (RESPOND Extension Study): Daniel Blackman, M.D., will present at 8:30 in room 342B.
- WATCHMAN LAAC Device: Real world net benefit of LAA closure at one year: safety and efficacy results in the EWOLUTION all-comers study: Martin W. Bergmann, M.D., will present at 11:47 in the Maillot room.
- Agent™ Paclitaxel-Coated Balloon Catheter**: Drug-coated Balloons for the treatment of coronary in-stent restenosis: a randomised, multicentre, controlled clinical study: Christian W. Hamm, Ph.D., will present at 14:45 in room 342B.
The company will also host an investor event and webcast on Tuesday, May 16, from 16:00 to 17:00 (CEST)/ 10:00 to 11:00 AM (EDT) to discuss its interventional cardiology and structural heart portfolios. The live webcast and replay will be accessible at www.bostonscientific.com/investors with the latter becoming available approximately one hour following the completion of the event.
*The LOTUS™ valve system is currently not available for use or sale.**In the U.S., the Agent™ Paclitaxel-Coated balloon catheter is investigational and not available for sale.
About Boston ScientificBoston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
CONTACTS:
U.S. Media: Trish Backes(612) [email protected]
European Media: Chiara Ennas+44 (0) 7766 [email protected]
Investor Relations: Susie Lisa, CFA(508) 683-5565 (office)[email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/boston-scientific-announces-schedule-of-presentations-at-europcr-2017-300454820.html
SOURCE Boston Scientific Corporation